Tenaya director granted 120K stock options

Tenaya Therapeutics director Karah Herdman Parschauer received a stock option grant for 120,000 shares of common stock.

Rhea-AI Filing Summary

Tenaya Therapeutics director Karah Herdman Parschauer received a stock option grant for 120,000 shares of common stock. The option has an exercise price of $0.7989 per share, expires on May 27, 2036, and will vest in full on May 28, 2027 or earlier, the day before the next annual stockholder meeting after the grant, if she continues as a service provider.

Insights

Equity compensation analyst

Routine director option grant with time-based vesting.

Tenaya Therapeutics, Inc. granted director Karah Herdman Parschauer options on 120,000 shares of common stock at an exercise price of $0.7989 per share. The grant is made under the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan.

The option vests in full on May 28, 2027, or earlier on the day immediately before the next annual stockholder meeting after the grant date, assuming continued service. This is a standard, compensation-related acquisition rather than an open-market purchase or sale.

The Form 4 shows no sales or exercises, only this single grant categorized as a derivative transaction. With total derivative holdings of 120,000 options following the transaction and no remaining unreported derivatives in the filing, this appears to be a straightforward award with neutral investment signaling.

Insider Trade Summary

Grant/Award: 120,000 shares

Grant/Award 1 txn

Insider Parschauer Karah Herdman

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	120,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to buy) — 120,000 contracts (Direct)

Footnotes (1)

1. F1. Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

Key Figures

Option grant size: 120,000 options Exercise price: $0.7989 per share Shares underlying option: 120,000 shares +4 more

7 metrics

Option grant size 120,000 options Stock Option (Right to buy) granted to director

Exercise price $0.7989 per share Conversion or exercise price for the option

Shares underlying option 120,000 shares Underlying Tenaya common stock

Total derivative shares after grant 120,000 options Total derivative holdings following transaction

Vesting date May 28, 2027 Full vesting or earlier before next annual meeting

Expiration date May 27, 2036 Option expiration

Transaction date May 28, 2026 Grant date of the stock option

Key Terms

Stock Option (Right to buy), Equity Incentive Plan, vesting, derivative transaction

4 terms

Stock Option (Right to buy) financial

"security_title: Stock Option (Right to buy)"

Equity Incentive Plan financial

"Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

vesting financial

"Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

derivative transaction financial

"derivativeTransactionCount: 1"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Karah Herdman Parschauer acquire in this Tenaya Therapeutics (TNYA) Form 4 filing?

She received a stock option grant for 120,000 shares of Tenaya Therapeutics common stock. The options were awarded as compensation, not bought in the market, and give her the right to purchase shares at a fixed exercise price if they vest and are exercised.

What is the exercise price of the Tenaya Therapeutics (TNYA) stock options granted to Karah Herdman Parschauer?

The options have an exercise price of $0.7989 per share. This means she can later buy up to 120,000 Tenaya common shares at $0.7989 each if she chooses to exercise, once the options are vested and before they expire.

When do Karah Herdman Parschauer’s Tenaya Therapeutics (TNYA) stock options vest?

The option will vest in full on May 28, 2027, or earlier, the day immediately before the date of the next annual stockholder meeting after the grant. Vesting depends on her continuing to be a service provider to Tenaya through that vesting date.

When do the Tenaya Therapeutics (TNYA) stock options granted to Karah Herdman Parschauer expire?

The options expire on May 27, 2036. After that expiration date she can no longer exercise them, even if they are vested. The long term to expiration is typical for director and employee equity incentive grants.

Is this Tenaya Therapeutics (TNYA) Form 4 a market purchase or sale of shares?

No, it reports a grant of stock options as compensation, not an open-market trade. The transaction code is A, described as a grant, award, or other acquisition, and the price per option at grant is shown as $0.0000.

Under which plan were the Tenaya Therapeutics (TNYA) options for Karah Herdman Parschauer granted?

The options were granted under the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. This plan provides equity-based awards to directors and other service providers, aligning their compensation with the company’s common stock performance over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 07:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parschauer Karah Herdman

(Last) (First) (Middle)

C/O TENAYA THERAPEUTICS, INC.

171 OYSTER POINT BLVD., 5TH FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$0.7989	05/28/2026		A		120,000		05/28/2027(1)	05/27/2036	Common Stock	120,000	$0	120,000	D

Explanation of Responses:

1. Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

	/s/ Jennifer Drimmer Rokovich, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)